UBS upgraded Hercules Capital's rating from Neutral to Buy, reflecting confidence in the company's strong financial stability and growth prospects. Hercules Capital, a specialty finance firm supporting tech and life sciences startups, boasts a BBB+ credit rating, low non-accruals at 0.3%, and a steady Net Investment Income of $2.00 per share. The company offers an attractive dividend yield of 11.1%, making it appealing for income-focused investors. Analysts set a 1-year price target of $18.46, indicating potential stock price appreciation.
Siemens Healthineers has begun separating its in vitro diagnostics business into a standalone company named Olyrian Diagnostics, expected to complete by mid-2028. This move aims to give the diagnostics unit a distinct market presence while continuing...
IQM Quantum Computers reported a 52% increase in order backlog to EUR 102.5 million by September 2026, driven by strong new orders including a EUR 33 million contract for its error-correction platform. Q3 revenue rose 51% year-over-year to EUR 8.9 mi...
IQM Quantum Computers reported a 52% increase in order backlog to €102.5 million by September 30, 2026, driven by major new contracts including the LUMI-IQ Halocene order. Q3 revenue rose 51% year-over-year to €8.9 million, with cash reserves at €260...
Financial institutions are increasingly deploying multi-agent AI systems to enhance banking and insurance workflows, with 59% piloting or deploying such systems. However, only 10% have achieved full enterprise-wide orchestration, highlighting challen...
Ademi LLP is investigating ServiceTitan for potential securities fraud related to alleged inaccurate statements about its financials and the rollout of its AI product, Max. This inquiry follows a drop in ServiceTitan's stock price and concerns about ...
